title: Thallium-201 SPECT in advanced non-small cell lung cancer: in relation with chemotherapeutic response, survival, distant metastasis and p53 status.
abstract: OBJECTIVE
  The aim of this study was to evaluate the relationship between 201Tl tumor uptake, chemotherapeutic response, metastasis, p53 status and survival in non-small cell lung cancer (NSCLC).
  
  
  METHODS
  A total of 23 patients underwent 201Tl SPECT. In 9 patients, 2nd 201Tl SPECT study were performed 1 week after the 3rd cycle of chemotherapy (ChT), and early (ER) and delayed (DR) tumor/normal lung ratios and retention indices (RI) were obtained. In 15 patients p53 status was assayed with immuno-histochemical staining. The patients were divided into subgroups after the 3rd cycle of ChT; responders [R(+) (n = 10)] and non-responders [R(-) (n = 13)], distant metastasis [(M1) n = 11] and [(M0) n = 12], and mutant p53 status [p(+) n = 7, p53(-) n = 8].
  
  
  RESULTS
  The differences for ER, DR and RI values between all of the subgroups were not statistically significant. ER and DR of responders decreased significantly after ChT; from to 2.46 to 1.36 (p = 0.04) and 2.29 to 1.53 (p = 0.04), respectively. In the non-responder group, both ER and DR slightly increased after ChT (p > 0.05).
  
  
  CONCLUSIONS
  Our results suggest that in NSCLC, there was a weak correlation between higher 201Tl ratios and positive response to chemotherapy, absence of distant metastasis, and p53(-) status. Significant 201Tl uptake decrease after chemotherapy indicates that delayed 201Tl uptake can be used in evaluating the chemotherapeutic response.
authors.affiliation: Department of Nuclear Medicine, Trakya University, Edirne, Turkey. cermik@trakya.edu.tr
authors.forename: Tevfik Fikret
authors.initials: TF
authors.lastname: Cermik
authors.forename: Mahmut
authors.initials: M
authors.lastname: Yüksel
authors.forename: Celal
authors.initials: C
authors.lastname: Karlikaya
authors.forename: Latife
authors.initials: L
authors.lastname: Doğanay
authors.forename: Mevlüt
authors.initials: M
authors.lastname: Türe
authors.forename: Sakir
authors.initials: S
authors.lastname: Berkarda
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002289:Carcinoma, Non-Small-Cell Lung / Q000000981:diagnostic imaging* / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D002945:Cisplatin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy* / Q000378:metabolism / Q000401:mortality; D008297:Male; D008875:Middle Aged; D019275:Radiopharmaceuticals; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D013223:Statistics as Topic; D016019:Survival Analysis; D013793:Thallium; D015899:Tomography, Emission-Computed, Single-Photon / Q000379:methods*; D016896:Treatment Outcome; D016159:Tumor Suppressor Protein p53 / Q000032:analysis
chemical_list: D019275:Radiopharmaceuticals; D016159:Tumor Suppressor Protein p53; C027549:thallium chloride; D005047:Etoposide; D013793:Thallium; D002945:Cisplatin